Group 1 - The core point of the article is the successful passing of the proposal to amend the company's articles of association during the fifth extraordinary general meeting of shareholders held on November 18, 2025, with a high approval rate of 98.76% overall and 70.03% among minority shareholders [1][4]. Group 2 - The meeting was held at 14:30 on November 18, 2025, in Haikou, Hainan Province, with both on-site and online voting options available [2]. - A total of 491 shareholders participated in the voting, representing 417,968,270 shares, which is 32.2167% of the company's total share capital [3]. - The voting results for the amendment proposal showed that 412,780,208 shares were in favor, accounting for 98.7587% of the votes cast, while 4,887,062 shares were against, and 301,000 shares were abstained [4]. Group 3 - The legal opinion provided by Beijing Dacheng (Haikou) Law Firm confirmed that the meeting's procedures, attendance, and voting results complied with relevant laws and regulations, deeming the resolutions valid [5].

Core Viewpoint - Haofan Bio provides a range of specialty chemical reagents, primarily focusing on peptide synthesis reagents and molecular building blocks, to numerous pharmaceutical research and production companies [2] Company Summary - Haofan Bio engages with various pharmaceutical R&D and production enterprises [2] - The company specializes in offering peptide synthesis reagents and molecular building blocks as part of its product portfolio [2]

Core Viewpoint - The company plans to sign a technology cooperation development contract with Nanjing University to jointly develop an anti-thrombotic small nucleic acid drug, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay a percentage of the annual revenue from the drug to Nanjing University for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, suggesting an imminent surge in the domestic market [1] - The company's strategic focus on cardiovascular treatments aligns well with the development of the new drug, enhancing its core competitiveness in research and injecting new momentum into its innovative drug portfolio [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, announced a collaboration with Nanjing University to develop "anti-thrombotic small nucleic acid drugs" with an investment of 15 million yuan [1] Group 1: Collaboration Details - The project is currently in the preliminary research stage and involves signing a technical cooperation development contract with Nanjing University [1] - The collaboration aims to conduct various preclinical research phases, including pharmacodynamic validation and drug-like property assessment of the target sequence [1] Group 2: Research Complexity - The research and development process is complex and involves multiple uncertainties, indicating potential challenges ahead [1]

Core Viewpoint - Tianyu Co., Ltd. announced the convening of its fifth board meeting on November 18, 2025, to review various proposals, including the confirmation of the audit committee members and the convener [1] Company Overview - For the first half of 2025, Tianyu Co., Ltd.'s revenue composition is as follows: 72.18% from generic drug raw materials and intermediates, 16.02% from CDMO raw materials and intermediates, 11.43% from formulations, and 0.37% from other sources [1] - As of the report date, the market capitalization of Tianyu Co., Ltd. is 9.2 billion yuan [1]

Core Viewpoint - The company plans to collaborate with Nanjing University for the joint development of "anti-thrombotic small nucleic acid drugs," with a transaction amount of 15 million yuan [1] Group 1 - The collaboration aims to leverage academic research for drug development [1] - The transaction amount indicates a significant investment in innovative pharmaceutical research [1]

Core Viewpoint - Company plans to sign a technology cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay Nanjing University a percentage of the annual revenue generated by the drug for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, positioning the company to seize market opportunities [1] - The target drug aligns with the company's strategic planning in the cardiovascular treatment field, enhancing its core competitiveness in research and injecting new momentum into the innovation drug product pipeline [1]

Core Viewpoint - Aoxiang Pharmaceutical (SH 603229) announced the convening of its fourth board meeting on November 18, 2025, to discuss the confirmation of the audit committee members and the convener [1] Company Summary - Aoxiang Pharmaceutical's revenue composition for the year 2024 is as follows: raw materials and intermediates account for 95.25%, while technical service fees make up 4.75% [1] - As of the report date, Aoxiang Pharmaceutical has a market capitalization of 8.5 billion yuan [1]

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：玛帕西沙韦（TG-1000）胶囊的上市审评目前处于正常 状态。审评过程中，监管部门要求补充核对标签说明书等相关文件，请问咱们补充材料是否提交，如果 没有提交大约什么时候提交材料。 健康元（600380.SH）11月18日在投资者互动平台表示，玛帕西沙韦（TG-1000）胶囊的上市审评目前 处于正常推进状态。对于审评过程中监管部门提出的补充核对标签说明书等相关文件的要求，公司高度 重视并已及时完成相关材料的整理与提交工作。后续，公司将持续与审评中心保持密切沟通，积极配合 各项审评工作，力争尽快推动产品审评流程有序推进。 ...

Group 1 - Shengxin Lithium Energy signed a framework agreement with Huayou Cobalt for the procurement of 221,400 tons of lithium salt products over five years [1] - Wehua New Materials' subsidiary plans to acquire 70% of He Yutai for 154 million yuan [1] - Xiamen Tungsten plans to invest 600 million yuan to establish a wholly-owned subsidiary for a project with an annual production capacity of 50,000 tons of high-performance battery materials [1][2] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 200-300 million USD for two VLCCs [3] - Hailianxun's stock will resume trading on November 19 after the end of the acquisition request period [5] - Yunnan Energy Investment obtained the development rights for a 25,000 kW wind power project [7] Group 3 - China Resources Double Crane's subsidiary received a drug registration certificate for Oxcarbazepine tablets [8] - Jincheng Pharmaceutical's subsidiary received a CEP certificate for glutathione raw materials [9] - Jinkong Electric plans to transfer 51% of Tongying Thermal Power to an affiliate for 266 million yuan [9] Group 4 - Clean Technology's subsidiary won a bid for a waste incineration power generation project in Thailand with a total investment of up to 4.27 million USD [12] - Tonglian Precision's shareholders set the transfer price for shares at 43.67 yuan each [13] - Hu Nong Commercial Bank's executives collectively purchased 259,100 shares of the company [13] Group 5 - Huatai Medical's subsidiary obtained a medical device registration certificate for polyethylene embolization microspheres [13] - Fosun Pharma's subsidiary's drug registration application was accepted by the National Medical Products Administration [13] - Xianhui Technology signed contracts worth 796 million yuan with multiple subsidiaries of CATL [15] Group 6 - Ningbo Fangzheng signed a strategic cooperation agreement with Huaxiang Qiyuan for the development of various robotic technologies [15] - Ruida Futures' vice president resigned for personal reasons [16] - Samsung Medical is expected to win contracts worth approximately 125 million yuan from the State Grid [17] Group 7 - Tianjin Pharmaceutical's injectable methylprednisolone sodium succinate received registration from Panama's Ministry of Health [19] - Yaxing Anchor Chain plans to invest up to 300 million yuan in a project for deep-sea floating equipment [20] - Zejing Pharmaceutical's clinical trial for ZG006 was approved by the National Medical Products Administration [21] Group 8 - Weiye Co., Ltd. won a bid for a project worth approximately 2.086 billion yuan [23] - Ruimao Tong plans to sell 8.5794 million repurchased shares [25] - Guangge Technology's shareholders plan to reduce their holdings by up to 3.99% [26] Group 9 - Hongsheng Development signed a debt restructuring contract for a total of 2 billion yuan [27][28] - Yatai Co., Ltd. plans to reduce its holdings by up to 1% [30] - Dexin Technology's shareholder plans to reduce its holdings by up to 1% [31] Group 10 - Yaji International's shareholder plans to reduce its holdings by up to 1% [33] - Shenzhen New Star's subsidiary received approval for trial production of a boron trifluoride project [35] - Shengyi Electronics plans to raise up to 2.6 billion yuan through a private placement [36]